Autoimmune hemolytic anemia secondary prevention

	Autoimmune hemolytic anemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Autoimmune hemolytic anemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Autoimmune hemolytic anemia secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Autoimmune hemolytic anemia secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Autoimmune hemolytic anemia secondary prevention
CDC on Autoimmune hemolytic anemia secondary prevention
Autoimmune hemolytic anemia secondary prevention in the news
Blogs on Autoimmune hemolytic anemia secondary prevention
Directions to Hospitals Treating Autoimmune hemolytic anemia
Risk calculators and risk factors for Autoimmune hemolytic anemia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Irfan Dotani

Overview

There is no significant role for secondary prevention of autoimmune hemolytic anemia.

There is no role for secondary prevention of autoimmune hemolytic anemia.
However, in patients at risk for hemolytic anemia who are suspected of having active hemolysis, screening for active hemolysis can be done via assessment of complete blood count (CBC), lactate dehydrogenase (LDH), total bilirubin, and reticulocyte count.^[1]